You are here

Home » Content

Oral antidiyabetiklerin kardiyovasküler etkileri

Cardiovascular effects of oral antidiabetic drugs

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Type 2 diabetes makes up more than 90 percent of dıabetes mellıtus (DM), being of a quite sıgnıfıcant risk factor for the development of coronary artery disease, and most of these patıents are reçuired to take oral antıdıabetic treat-ment. Upon consıdered that the main cause of the deaths in type 2 DM is cardiovascular diseases, ıt is necessary that the effects of the drugs used for these patıents on cardiovascular system be well-known. İn thıs artıcle. ıt has been tried to be presented a general poınt of vievv of oral antıdiabetic drugs knovvn to have various direct and indirect car¬diovascular effects över these influences.
Bookmark/Search this post with
Abstract (Original Language): 
Koroner arter hastalığı gelişimi için oldukça önemli bir risk faktörü olan dıyabetes mellitusun (DM) % 90 dan fazlasını tıp-2 diyabet oluşturur ve bu hastaların çoğu oral antıdiyabetik tedavi almak zorundadır Tıp-2 DM'da esas ölüm nedeninin kardiyovasküler hastalıklar olduğu düşünüldüğünde bu hastalarda kullanılacak ilaçların kardiyovasküler (KV) sistem üzerine olan etkilerinin iyi bilinmesi gerekir. Bu yazıda doğrudan veya dolaylı yoldan çeşitli KV etkilere sahip oldukları bilinen oral antidiyabetiklerin bu etkilerine genel bir bakış sunulmaya çalışılmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-oral-antidiyabetiklerin-kardiyovaskuler-etkileri.pdf
  • 2
67-71
  • Turkish

REFERENCES

References: 

1. de MarcoR. Locatelli F, Zoppıni G. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Srudy. Diabetes Care 1999;22:756-61.
2. Rosenstock J. Samols E, Muchmore DB, Schneider J. Glimepiride. a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patıents. Glimepiride Study Group. Diabetes Care 1996,19.1 194¬9.
3. Brady FA. Terzıc A. The sulfonylurea controversy: more guestions from the heart. J Am Coll Cardioi 1998;31:950-6.
4. Duncker DJ, Van Zon NS, Altman JD. Role of K + ATP channels in coronary vasodilation during exercise. Orculation 1993;88:1245-53.
5. Cole WC, McPherson CD, Sontag D. ATP - regulated K + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
6. Toombs CF, McGee S, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemîa. Circulation 1992,'86.986-94.
7. Garratt KİM, Brady PA Hassinger NL. Sulfonylurea drugs increase early mortality in patıents vvith diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardioi 1999,33:1 19-24.
8. Klepzig H, Kober G, Matter C. Sulfonylureas and ischaemic
preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibendamide. Eur Heart J 1 999;20:439-46.
9. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia 1 995;38: M 6-2 I.
10. Fleming A. FDA approach To the regulation of drugs for
diabetes. Am Heart J 1999; 138:338-45.

I1 Adams JF. Clark JS. Ireland JT Malabsorpuon of vitamin BI2 and intrınsıc factor secretıon during bıguanıde [herapy Dıabetologıa 1983.24.16-8
12-Mayer EL JacoDsen DW. Robınson K Homocysteıne and coronary aiherosclerosıs J Am Coll Cardioi 1996.27:51 7¬27
13 Mısbın Rl. Green L Stadel BV. et al. Lactıc acıdosıs in patıents wıth diabetes treated wıth metformin N Engl J Med 1998.338.265-6
l4Marcheftı P, Navalesı R Pharmacokınetıc-pharmacody-namıc relatıonshıps of oral hypoglycaemıc agents An update Clın Pharmacokınet 1989,16 I 00-28
15 Şener SM. Iltz JL Thams J. Campbell RK Metformin hydrochlorrde ın the treatment of type 2 diabetes meltus a climcal revıevv wıth a focus on dual theraphy Clın Ther 2003; 25:2991-3026
l7.Mather KJ. Verma S, Anderson TJ Improved endothelial functıon wıth merformın m type 2 diabetes mellıtus J Am Coll Cardioi 2001.37.1344-50
!8Kao J, Tobıs J, McClelland RL Investıgators ın the Preventıon of Restenosıs With Tranılast and Its Outcomes Trıal Relatıon of metformin treatment to clınıcal events ın dıabetıc patıents undergoıng percutaneous ınterventıon Am J Cardioi 2004.93:1347-50.
19 Fısman EZ. Tenenbaum A Motro M, Adler Y Oral antıdı-abetıc therapy ın patıents wıth heart dısease A cardıo-logıc standpoint Herz 2004;29:290-0.
20 Saltıel AR, Olefsky JM Thıazolıdınedıones ın the treatment of insulın resıstance and type II diabetes Diabetes 1996;45:1661-9

21 Duval C. Chınettı G. Trotteın F The role of PPARs ın atherosclerosıs Trends Mol Med 2002.8 422-30
22 Fonseca VA Management of diabetes mellıtus and insulın resıstance ın patıents wıth cardiovascular dısease Am J Cardioi 2003.92:50-60.
23 Bakrıs G. Vıbertı G. Weston WM Rosıglıtazone reduces unnary albumın excretıon m type II diabetes J Hum Hypertens 2003.17.7-12
24 Goetze S. Bungenstock A Czupalla C Leptın ınduces endothelial celi mıgratıon through Akt. vvhıch ıs ınhıbıted by PPARgamma-Jıgands Hypertensıon 2002.40 748-54
25 Fısman EZ, Motro M. Tenenbaum A Impaıred fastıng giu-cose concentratıons ın nondıabetıc patıents wıth ıschemıc heart dısease: a marker for a worse prognosıs Am Heart J 2001.141:485-90.
26 Chıasson JL Josse RG. Gomıs R STOP-NIDDM Traıl Research Group Acarbose for preventıon of type 2 dia-betes mellıtus: the STOP-NIDDM randomısed trıal Lancet 2002.359:2072-7
27 Rao SV. Bethel MA Feınglos MN Treatment of diabetes mellıtus: ımplıcatıons of the use of oral agents Am Heart J 1999;138:334-7

Thank you for copying data from http://www.arastirmax.com